# First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

> **NCT05361395** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 184 (actual)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Tarlatamab
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Atezolizumab
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05361395
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-24
- **Primary completion:** 2028-08-28
- **Final completion:** 2028-08-28
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361395, "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05361395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*